Dell's AI server business is growing faster than even optimists expected

Dell raised its full-year AI server revenue target to $60 billion, backed by a $51.3 billion backlog, after crushing earnings estimates by nearly 60% and posting 88% year-over-year revenue growth in Q1.

The raise-on-a-beat pattern is the tell here: when a company lifts guidance the same day it reports a historic quarter, it is signaling that demand visibility is strong enough to commit to, not just celebrate.

Gap and American Eagle are both telling investors the consumer is fine while their own numbers say otherwise

Gap cut its full-year sales outlook and American Eagle's weak annual guidance sent shares down nearly 12%, even as executives at both companies insisted the broader economy is healthy.

The contradiction is the story: when management language and forward guidance point in opposite directions, the guidance is almost always the more honest signal.

Replimune's FDA deal signals a more permissive regulatory climate for previously rejected drugs

Replimune reached an agreement with the FDA to resubmit its twice-rejected melanoma drug application, a development that sent the stock up more than 85% and arrived shortly after a change in FDA leadership.

Whether the timing is coincidence or cause, other biotech companies with stalled applications will be watching this outcome very carefully as a signal of what the new regulatory posture actually means in practice.